Search

everythinglearnresearchcommunity

for

Search:↓

A woman with rheumatoid arthritis had a unique type of scarring hair loss not caused by infection, requiring early treatment to avoid permanent hair loss.

The MPV/PC ratio can help assess disease activity in alopecia areata.

The study concluded that patients with total hair loss and recurring hair loss had an earlier onset, longer-lasting condition, and a greater negative impact on their quality of life, with allergic conditions linked to more severe hair loss.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Minoxidil and finasteride treat hair loss; more research needed for other options.

Latanoprost can effectively treat eyelash hair loss, with 45% of patients showing hair regrowth and no reported side effects.

Plasmacytoid dendritic cells are a key factor in causing hair loss in alopecia areata and could help differentiate it from other hair loss conditions.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

People with alopecia areata often have lower vitamin D levels and more inflammation, suggesting vitamin D might be involved in the condition.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Some people with heavy hair shedding might actually have a hidden form of alopecia, which can be identified by specific hair changes.

Bimatoprost is safe but not effective for severe eyelash loss from alopecia areata, possibly helping those with less loss.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Azelaic acid and anthralin are similarly effective for treating patchy hair loss.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Korean Red Ginseng may help improve hair regrowth when used with corticosteroid injections for Alopecia Areata.

Two transplant patients on cyclosporine unexpectedly developed hair loss.

The combination of cyclosporine and PUVA might help treat severe alopecia areata.

Decreased CD200 in hair follicles may cause immune issues in some alopecia areata cases.

People with alopecia areata have higher levels of a heart disease marker than those without hair loss.

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

Effective treatments for severe alopecia areata are still lacking.

The laser comb did not improve hair regrowth in mice with alopecia areata.

Certain factors like allergies, nail problems, and hair loss patterns can predict how well someone with patchy hair loss will respond to skin cream treatments.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Hair transplantation can effectively treat stable eyebrow hair loss in alopecia areata patients.